CDK6 9-IN-1 (compound 66) is a potent dual inhibitor of CDK 6 and CDK 9 that can be administered orally. It exhibits inhibitory activity with IC 50 values of 40.5 nM and 39.5 nM against CDK6 and CDK9, respectively.
Substance P (1-9) is a nonapeptide that reduces the inactivation of substance P in the guinea-pig ileum and urinary bladder, and is responsible for various excitatory effects on central and peripheral neurons.
CDK7 9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7 9 (CDK7 9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7 9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7 9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for such investigations.
This is an N-terminal fragment of beta amyloid. It consists of amino acid residues 1 to 9. Truncated beta amyloid peptide (10-40) still forms amyloid fibrils and shows fibril polymorphism.
Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].
HIV-1 inhibitor-9 exhibits potent inhibition activity at low nanomolar concentrations against both the wild-type (WT) HIV-1 strain and multiple strains that have developed resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs).